[Skip to Navigation]
Views 370
Citations 0
Comment & Response
February 2017

Intravenous Fentanyl and Potential Mortality

Author Affiliations
  • 1Department of Anesthesiology, Louisiana State University Health Science Center, New Orleans
  • 2Departments of Physical Medicine & Rehabilitation and Anesthesiology, Medical College of Wisconsin, Milwaukee
  • 3Department of Orthopedics and Rehabilitation, University of Wisconsin School of Medcine and Public Health, Madison
JAMA Intern Med. 2017;177(2):290-291. doi:10.1001/jamainternmed.2016.8753

To the Editor The Invited Commentary in a recent issue of JAMA Internal Medicine by Green and Gilbert1 is interesting and informative. Green and Gilbert commended the Research Letter by Arens and colleagues2 that reported a case series of counterfeit alprazolam (Xanax; Pfizer) tablets containing fentanyl and etizolam. Green and Gilbert emphasize that the current outbreak of illicitly synthesized fentanyl is remarkable for its wider geographic reach, more diverse groups of users, and a variety of fentanyl analogues being synthesized illicitly in clandestine laboratories.1

Add or change institution